Jim Cramer on Moderna: “Even Though the Stock’s on the Mend, There Are Many Pharma and Biotech Names That I Like Better”

Moderna, Inc. (NASDAQ:MRNA) is one of the noteworthy S&P 500 stocks Jim Cramer highlighted. Cramer highlighted that the company is likely to remain unprofitable for “years to come,” as he stated:

Next, let’s go back to the second-best performer in the S&P for January, and that’s Moderna. That was up nearly 50%, and this was… a wild ride. After practically printing money during the pandemic thanks to its COVID vaccine, Moderna plunged 95% from its peak in 2021 to its lows last November, really gaffed a lot of people. But over the past couple of months, the stock’s found new life, nearly doubling from its lows. Now, the move started after a very positive investor day event in November, where Moderna said it would return to revenue growth in 2026 for the first time since 2021. Big deal.

I also think that Wall Street has seen what Health and Human Services Secretary, RFK Jr., wants to do to the vaccine industry, and maybe it’s just not as frightening as people thought. And Moderna might finally deliver those personalized cancer vaccines that they told me about a very long time ago. That said, Moderna remains deeply unprofitable. It’s likely to remain that way for years to come. Even though the stock’s on the mend, there are many pharma and biotech names that I like better. I’ve been looking at Regeneron over the weekend. That’s really made a nice comeback.

Photo by Ian Hutchinson on Unsplash

Moderna, Inc. (NASDAQ:MRNA) makes mRNA medicines and vaccines to protect against illnesses like the flu, COVID-19, and some other viruses. The company also works on treatments for cancer and rare diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.